<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of hemostasis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of hemostasis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of hemostasis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pier Mannuccio Mannucci, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hemostasis is the process of blood clot formation at the site of vessel injury. When a blood vessel wall is disrupted, the hemostatic response must be quick, localized, and carefully regulated. Abnormal bleeding or thrombosis (ie, nonphysiologic blood clotting not required for hemostatic regulation) may occur when specific elements of these processes are missing or dysfunctional.</p><p class="bulletIndent1"><span class="glyph">●</span>The pathways of thrombin-mediated fibrin clot formation and plasmin-mediated clot lysis are linked and carefully regulated  (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">figure 3</a>) [<a href="#rid1">1</a>]. When they work in coordinated harmony, a clot is laid down initially to stop bleeding, followed by eventual clot lysis and tissue remodeling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal bleeding can result from diminished thrombin generation (eg, due to factor VIII deficiency) or enhanced clot lysis (eg, due to alpha-2-antiplasmin deficiency). Conversely, excessive production of thrombin (eg, due to an inherited thrombophilia) can lead to thrombosis.</p><p></p><p>The elements responsible for normal hemostasis will be reviewed here. Approaches to the patient with abnormal bleeding or abnormal thrombosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a> and  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.) </p><p>The uses of platelet function testing and coagulation assays to diagnose hemostatic abnormalities are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing"</a> and  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PHASES OF THE HEMOSTATIC PROCESS</span><span class="headingEndMark"> — </span>Although the clotting process is a dynamic, highly interwoven array of multiple processes [<a href="#rid2">2</a>], it can be viewed as occurring in phases, which are discussed in detail in the following sections:</p><p class="bulletIndent1"><span class="glyph">●</span>Endothelial injury and formation of the platelet plug. (See <a class="local">'Formation of the platelet plug'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Propagation of the clotting process by the coagulation cascade. (See <a class="local">'Clotting cascade and propagation of the clot'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Termination of clotting by antithrombotic control mechanisms. (See <a class="local">'Control mechanisms and termination of clotting'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Removal of the clot by fibrinolysis. (See <a class="local">'Clot dissolution and fibrinolysis'</a> below.)</p><p></p><p>The site of clot formation (artery or vein) and the rate of blood flow also have important effects on clot composition. (See <a class="local">'DIfferences in blood clotting in veins versus arteries'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">FORMATION OF THE PLATELET PLUG</span><span class="headingEndMark"> — </span>Platelets are activated at the site of vascular injury to form a platelet plug that provides the initial hemostatic response to stop bleeding. (See  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Conceptual framework'</a> and  <a class="medical medical_review" href="/z/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs"</a>.)</p><p>Injury to the endothelium leads to exposure of the circulating blood to subendothelial elements from which it would normally be protected, and endothelial cell activation may further promote recruitment of platelets, other cell types, and procoagulant factors. (See  <a class="medical medical_review" href="/z/d/html/1330.html" rel="external">"The endothelium: A primer"</a>.)</p><p>The functional response of activated platelets involves four different processes:</p><p class="bulletIndent1"><span class="glyph">●</span>Adhesion – The deposition of platelets on the subendothelial matrix</p><p class="bulletIndent1"><span class="glyph">●</span>Aggregation – Platelet-platelet cohesion</p><p class="bulletIndent1"><span class="glyph">●</span>Secretion – The release of platelet granule proteins</p><p class="bulletIndent1"><span class="glyph">●</span>Procoagulant activity – The enhancement of thrombin generation</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Platelet activation</span><span class="headingEndMark"> — </span>There are a number of physiologic platelet stimuli including adenosine diphosphate (ADP), <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, thrombin, and collagen. ADP and epinephrine are relatively weak platelet activators, while collagen and thrombin are the most potent platelet activators. </p><p>The spatial hierarchy of platelet agonists under flow conditions at the site of vascular injury begins with thrombin, which activates a core of platelets in the core of the hemostatic plug [<a href="#rid3">3</a>]. ADP activates more loosely packed platelets in a shell overlying the core, and thromboxane provides a critical activation in the shell region. (See <a class="local">'Platelet secretion'</a> below and <a class="local">'Prostacyclin and thromboxane'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h3">Collagen</span><span class="headingEndMark"> — </span>The intact endothelium prevents the adherence of platelets by the production of nitric oxide and prostacyclin. Intimal injury impairs these processes and exposes subendothelial elements such as microfibrils, laminin, and collagen. These factors lead to the adherence of platelets, platelet activation, and secretion.</p><p>Integrins are a superfamily of adhesive protein receptors that are found in many different cell types. They typically exists as a heterodimer composed of an alpha subunit and a beta subunit. The integrin glycoproteins GPIa/IIa (also known as alpha2 beta1) and GPVI are the two major platelet collagen receptors, playing critical roles in platelet adhesion and activation, respectively [<a href="#rid4">4</a>]. Patients with GPIa/IIa deficiency generally have mild bleeding diathesis, while severe spontaneous bleeding has been reported with platelet GPVI deficiency.</p><p class="headingAnchor" id="H6"><span class="h3">Thrombin</span><span class="headingEndMark"> — </span>Thrombin activation of cells is mediated by a family of G-protein coupled protease-activated receptors (PARs) [<a href="#rid5">5-8</a>]. Platelets have a dual receptor system for thrombin, with two distinct receptors (PAR-1 and PAR-4). Thrombin cleaves the amino-terminal exodomain of PAR, exposing a new amino-terminus, which then serves as a tethered ligand that binds intramolecularly to the body of the receptor to initiate transmembrane signaling [<a href="#rid9">9</a>]. </p><p>PAR-1 is a high-affinity receptor that mediates the effect of thrombin at low concentrations; PAR-4 is a low-affinity receptor that requires high levels of thrombin for activation [<a href="#rid5">5</a>]. <a class="drug drug_general" data-topicid="95242" href="/z/d/drug information/95242.html" rel="external">Vorapaxar</a> is an oral PAR-1 antagonist developed as an antiplatelet agent [<a href="#rid10">10-12</a>]. </p><p>In an animal model of laser-induced vascular injury, it was shown that thrombin, rather than collagen, is the major agonist leading to platelet activation [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H385566943"><span class="h3">ADP</span><span class="headingEndMark"> — </span>ADP binds to two G-protein coupled purinergic receptors, P2Y<sub>1</sub> and P2Y<sub>12</sub>. Activation of P2Y<sub>1</sub> leads to calcium mobilization, platelet shape change, and rapidly reversible aggregation; activation of P2Y<sub>12</sub> leads to platelet secretion and more stable aggregation [<a href="#rid14">14</a>]. ADP stored in the dense granules is released from platelets upon platelet activation and functions in a paracrine/autocrine fashion to recruit additional platelets and amplify platelet aggregation. <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> blocks the activation of P2Y<sub>12</sub>.</p><p class="headingAnchor" id="H7"><span class="h2">Platelet adhesion</span><span class="headingEndMark"> — </span>Following activation, platelets undergo significant shape changes, producing elongated pseudopods that make the platelets extremely adhesive. Platelet adhesion is primarily mediated by the binding of platelet surface receptor GPIb/IX/V complex to von Willebrand factor (VWF) in the subendothelial matrix [<a href="#rid15">15</a>]. Deficiency of any component of the GPIb/IX/V complex or VWF leads to congenital bleeding disorders: Bernard-Soulier disease [<a href="#rid16">16</a>] and von Willebrand disease, respectively. (See  <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease"</a> and  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Conceptual framework'</a>.)</p><p>In addition, there are other adhesive interactions that contribute to platelet adhesion. One example is binding of the platelet collagen receptor GPIa/IIa to collagen fibrils in the matrix [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Platelet aggregation</span><span class="headingEndMark"> — </span>Platelet activation results in conformational changes in the GPIIb/IIIa receptor on the platelet surface leading to binding of VWF and fibrinogen, resulting in platelet-platelet cohesion or aggregation [<a href="#rid18">18-20</a>].</p><p>GPIIb/IIIa is also a member of the integrin superfamily. The GPIIb/IIIa complex (integrin alphaIIb beta3) is the most abundant receptor on the platelet surface, with about 80,000 complexes per platelet. GPIIb/IIIa does not bind fibrinogen on nonstimulated platelets. However, following platelet stimulation (eg, by thrombin, collagen, or ADP), GPIIb/IIIa undergoes a conformational change and is converted from a low-affinity to a high-affinity fibrinogen receptor, a process referred to as "inside-out" signaling (since the conformational change in the external cell surface exposed GPIIb/IIIa complex is mediated by changes in the intracellular cytosolic portion ["cytoplasmic tail"] of the complex). Fibrinogen is a divalent symmetrical molecule, able to bind to two activated GPIIb/IIIa complexes on two different platelets, thus crosslinking them. (See  <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">"Disorders of fibrinogen"</a> and  <a class="medical medical_review" href="/z/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs", section on 'Integrin alphaIIbbeta3 (GPIIb/IIIa) binding to fibrinogen, activation, and platelet aggregation'</a>.)</p><p>In addition to mediating platelet aggregation, when GPIIb/IIIa binds to immobilized VWF (on exposed subendothelial matrix), the cytosolic portion of the activated GPIIb/IIIa complex binds to the platelet cytoskeleton, resulting in platelet spreading and clot retraction, which has been referred to as "outside-in" integrin signaling. Thus, the GPIIb/IIIa complex integrates receptor-ligand interactions that occur on the external face of the membrane with cytosolic events in a bidirectional fashion [<a href="#rid21">21,22</a>]; it is the final common pathway for platelet aggregation, irrespective of the mode of platelet stimulation.</p><p>The importance of GPIIb/IIIa is illustrated by the congenital bleeding disorder Glanzmann thrombasthenia, which is characterized by mutations in the gene for either the alphaIIb or the beta3 subunit [<a href="#rid23">23</a>], as well as the clinical utility of GPIIb/IIIa antagonists in the treatment of coronary artery disease. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Glycoprotein IIb/IIIa inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Glycoprotein IIb/IIIa inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Glanzmann thrombasthenia'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Platelet secretion</span><span class="headingEndMark"> — </span>Platelets contain two types of granules: alpha granules and dense granules (which appear dense on transmission electron micrographs). The alpha granules contain many proteins including fibrinogen, von Willebrand factor, thrombospondin, platelet-derived growth factor (PDGF), platelet factor 4, and P-selectin. Dense granules contain ADP, ATP, ionized calcium, histamine, and serotonin. Platelets secrete a variety of substances from their granules upon cell stimulation:</p><p class="bulletIndent1"><span class="glyph">●</span>ADP and serotonin stimulate and recruit additional platelets [<a href="#rid24">24</a>]. Platelet-released serotonin normally causes vasodilation; however, it can induce vasoconstriction in the presence of damaged or abnormal (dysfunctional) endothelium. ADP-activated platelets increase the surface expression of intercellular adhesion molecule (ICAM)-1 on endothelial cells [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibronectin and thrombospondin are adhesive proteins that may reinforce and stabilize platelet aggregates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinogen is released from platelet alpha granules, providing a source of fibrinogen at sites of endothelial injury in addition to that present in plasma [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thromboxane A2, a prostaglandin metabolite, promotes vasoconstriction and further platelet aggregation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Constitutive release of proangiogenic cytokines such as VEGF A and growth factors or trophogens (eg, PDGF) from platelets serves to maintain the tight vascular contact (vascular adherens junction) between endothelial cells and the overall vascular integrity at the capillary level [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent1">At the site of vascular injury, the release of these growth factors probably mediates tissue repair physiologically and, at a site of repeated injuries, may contribute to the development of atherosclerosis and coronary reocclusion following angioplasty. (See  <a class="medical medical_review" href="/z/d/html/1498.html" rel="external">"The role of platelets in coronary heart disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Release of the thiol isomerase, protein disulfide isomerase (PDI), by platelets and disrupted vessel wall cells may serve to activate tissue factor and enhance the generation of fibrin and platelet thrombus formation at sites of vascular injury [<a href="#rid28">28,29</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Procoagulant activity</span><span class="headingEndMark"> — </span>Platelet procoagulant activity is an important aspect of platelet activation and involves both exposure of procoagulant phospholipids, primarily the anionic phosphatidylserine, and the subsequent assembly of the enzyme complexes in the clotting cascade on the platelet surface [<a href="#rid30">30</a>]. This is an important example of the close interrelationship between platelet activation and activation of the clotting cascade that has been referred to as "cell-based" coagulation [<a href="#rid31">31</a>]. It plays a key role in the functional assembly of the clotting cascade on the activated platelet surface in areas of arterial high blood flow. (See <a class="local">'Multicomponent complexes'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h1">CLOTTING CASCADE AND PROPAGATION OF THE CLOT</span></p><p class="headingAnchor" id="H23919864"><span class="h2">Overview of clot propagation</span><span class="headingEndMark"> — </span>The central feature of the clotting cascade is the sequential activation of a series of proenzymes or inactive precursor proteins (zymogens) to active enzymes, resulting in significant stepwise response amplification. As an example, the generation of a small number of factor VIIa molecules will activate many molecules of factor X, which in turn generates even larger numbers of thrombin molecules, which then converts fibrinogen to fibrin  (<a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">figure 2</a>). The resultant local generation of fibrin, in turn, enmeshes and reinforces the platelet plug.</p><p>The function of the active enzymes is markedly facilitated by the formation of multiple component macromolecular complexes, such as the tenases (X-ase) that activate factor X and the prothrombinase which produces thrombin from prothrombin. (See <a class="local">'Multicomponent complexes'</a> below.)</p><p>All of the procoagulants are synthesized in the liver except for von Willebrand factor (VWF), which is synthesized in megakaryocytes and endothelial cells, and factor VIII, which is produced in endothelial cells in the liver as well as other tissues such as lymphatics and renal glomeruli [<a href="#rid32">32-34</a>]. VWF and factor VIII are co-expressed in postcapillary high endothelial venules but not in most other endothelial cells. VWF stabilizes factor VIII. (See  <a class="medical medical_review" href="/z/d/html/1316.html" rel="external">"Biology and normal function of factor VIII and factor IX"</a> and  <a class="medical medical_review" href="/z/d/html/1309.html" rel="external">"Pathophysiology of von Willebrand disease", section on 'VWF protein'</a>.)</p><p>Post-translational modification of these factors is known to occur [<a href="#rid35">35</a>]. The best characterized modifications occur in the vitamin K-dependent procoagulants (ie, prothrombin, factors VII, IX, and X) and anticoagulants (ie, protein C and protein S). For each of these factors, vitamin K-dependent carboxylated glutamic acid residues function as calcium-binding sites that are important in the assembly of the membrane-bound macromolecular procoagulant complexes [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a>.)</p><p>Traditionally, the clotting cascade is depicted as consisting of an intrinsic and extrinsic pathway  (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a>). This view of coagulation is useful for interpreting in vitro tests of coagulation. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The intrinsic pathway is initiated by the exposure of blood to a negatively charged surface (such as celite, kaolin, or silica in the in vitro activated partial thromboplastin clotting time [aPTT]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The extrinsic pathway is activated by tissue factor exposed at the site of injury or tissue factor-like material (thromboplastin, TPL in the in vitro prothrombin clotting time [PT]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both pathways converge on the activation of factor X which, as a component of prothrombinase, converts prothrombin to thrombin, the final enzyme of the clotting cascade. Thrombin converts fibrinogen from a soluble plasma protein into an insoluble fibrin clot (tested in the in vitro thrombin time [TT]).</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Thrombin generation</span><span class="headingEndMark"> — </span>While the classical view of the clotting cascade based on intrinsic and extrinsic pathways has been useful in the interpretation of in vitro coagulation tests (eg, PT and aPTT), it may not be physiologically accurate.</p><p>It is now established that the generation or exposure of tissue factor at the wound site and its interaction with activated factor VII (factor VIIa)  (<a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">figure 2</a>) is the <strong>primary</strong> physiologic event in initiating clotting [<a href="#rid37">37</a>]. The small initial amount of thrombin generated then activates factor XI in a feedback manner, leading to <strong>amplification</strong> of thrombin generation. This was shown via the time course of thrombin generation, which demonstrated an initiation phase with only a small amount of thrombin being generated, followed by a propagation phase consisting of the bulk of thrombin generation, and finally cessation of thrombin generation [<a href="#rid38">38</a>].</p><p>Standard laboratory clotting tests, which detect initial fibrin clot formation, primarily measure the initiation and not the propagation phase of clotting. The initiation phase is largely mediated by the activation of factor X by tissue factor/factor VIIa, giving rise to a small amount of thrombin  (<a class="graphic graphic_figure graphicRef97057" href="/z/d/graphic/97057.html" rel="external">figure 4</a>), which in turn activates factor V, factor VIII, factor XI, and platelets, exposing anionic phospholipids on the platelet surface to support the assembly of the multi-component enzyme complexes (intrinsic tenase and prothrombinase) [<a href="#rid39">39</a>]. Thus, the initial small amount of generated thrombin primes the clotting cascade and activates platelets, which then leads to explosive thrombin generation. This is illustrated in the Amplification and Propagation phases in the figure  (<a class="graphic graphic_figure graphicRef75450" href="/z/d/graphic/75450.html" rel="external">figure 5</a>).</p><p>At least two cell types play important roles in the initial phases of thrombin generation.</p><p class="bulletIndent1"><span class="glyph">●</span>Activated platelets in the initial platelet plug adherent to the endothelium provide a phospholipid surface that promotes assembly of multicomponent complexes. (See <a class="local">'Multicomponent complexes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activated endothelial cells at the site of injury provide binding sites for coagulation factors and other procoagulant effects.</p><p></p><p>The prominent role of endothelial cells rather than platelets to thrombin generation was illustrated in a study using a mouse model of arteriolar injury in which accumulation of fluorescently labeled activated clotting factors was imaged in vivo [<a href="#rid40">40</a>]. Fluorescently labeled factors Xa and Va bound to the endothelium outside the edges of the initial platelet plug and did not bind to platelets a small distance from the site of injury. When platelet thrombus formation at the injured site was blocked extensively, using an inhibitor of platelet aggregation or an animal lacking the platelet thrombin receptor PAR4, accumulation of factors Xa, Va, and fibrin at the site of injury was virtually unaffected.</p><p>These findings may explain why patients with severe thrombocytopenia or inherited platelet defects do not have typical findings associated with impaired coagulation such as tissue hematomas and joint bleeding  (<a class="graphic graphic_table graphicRef77834" href="/z/d/graphic/77834.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H14"><span class="h2">Multicomponent complexes</span><span class="headingEndMark"> — </span>Four multicomponent macromolecular complexes play a major role in the coagulation pathways: three procoagulant complexes (extrinsic and intrinsic X-ase and prothrombinase) and one anticoagulant complex. These complexes consist of the enzyme, a cofactor protein, the enzyme substrate, assembled on cellular membrane components (anionic phospholipid surfaces) in the presence of calcium  (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extrinsic X-ase (ten-ase)</strong> – Consists of<sup> </sup>activated factor VII (factor VIIa) as the protease, tissue factor as the cofactor, and factor X (Stuart factor) as the substrate [<a href="#rid41">41-43</a>]. Tissue factor/FVIIa activate both factor X and factor IX [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intrinsic X-ase (ten-ase)</strong> – Consists of factor IXa as the protease, activated factor VIII (factor VIIIa) as the cofactor, and factor X as the substrate [<a href="#rid46">46</a>]. Factor IXa can be generated by tissue factor/FVIIa or via activation of the intrinsic pathway, either directly or indirectly via thrombin-induced activation of factor XI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prothrombinase</strong> – Consists of factor Xa as the protease, factor Va as the cofactor, and prothrombin (factor II) as the substrate. Data from cryo-electron microscopy (cryo-EM) demonstrate that the role of the factor Va cofactor is a structural one, serving as a scaffold to allow efficient cleavage (activation) of prothrombin by factor Xa [<a href="#rid47">47</a>]. This is analogous to the activation of protein C by the thrombin/thrombomodulin complex, in which thrombomodulin serves as a scaffold to align protein C with thrombin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein C anticoagulant complex</strong> – Consists of thrombin (factor IIa) as the enzyme, thrombomodulin as the cofactor, and protein C as the substrate. In addition, endothelial protein C receptor (EPCR), which is primarily expressed on the endothelium of large blood vessels, functions as a receptor for protein C and further accelerates the activation of protein C by the thrombin/thrombomodulin complex [<a href="#rid48">48</a>].</p><p></p><p>All the activated clotting factors in the clotting cascade (ie, factors VIIa, XIa, IXa, Xa, and thrombin [IIa]) are trypsin-like serine proteases (with serine as a major component of their catalytic site). Despite their structural relatedness, they display remarkable specificity towards their substrates (eg, FIXa activates factor X but not prothrombin (factor II) or fibrinogen). This substrate specificity results from the structural requirement of the substrate to be aligned properly ("docked") with the enzyme before proteolytic cleavage of the substrate can take place. This docking is mediated by an exosite on the enzyme surface that lies outside the active catalytic site  (<a class="graphic graphic_figure graphicRef97057" href="/z/d/graphic/97057.html" rel="external">figure 4</a>) [<a href="#rid49">49</a>].</p><p>The advantages of these multicomponent enzyme complexes can be illustrated by the prothrombinase complex [<a href="#rid50">50</a>]. When platelets are activated, anionic lipids – primarily phosphatidylserine – become exposed on the platelet surface, and factor V, stored in platelet granules, is released and bound to these anionic lipids. Factor V is activated to factor Va by the initial trace amount of thrombin generated from interactions between tissue factor and factor VIIa at the wound site. Together with the appropriate anionic membrane phospholipids and calcium, this activated factor Xa and its cofactor, factor Va, form the prothrombinase complex, which cleaves prothrombin (factor II) to thrombin (factor IIa).</p><p>Because of its extremely favorable local proximity, thrombin generation by the prothrombinase complex is approximately 300,000 times more efficient compared with that generated by factor Xa and prothrombin alone. In addition, factor Xa bound to factor Va is also relatively protected from inhibition by circulating inhibitors such as antithrombin. The net effect is that thrombin generation is dramatically enhanced on the surface of activated platelets and restricted to sites of vascular injury.</p><p>The importance of the procoagulant effect of platelets in the assembly of multicomponent complexes is illustrated by congenital platelet function disorders in which the platelet membrane phospholipids do not change in response to platelet activation. Scott syndrome is an autosomal recessive disorder caused by mutation of TMEM16F, a protein partly responsible for lipid scramblase activity [<a href="#rid30">30,50-54</a>]. This protein forms a calcium-activated channel that promotes the "scrambling" (ie, disrupting the membrane gradient) of phosphatidylserine, moving it from the inner leaflet of the platelet plasma membrane to the outer leaflet [<a href="#rid54">54</a>]. Activated platelets with phosphatidylserine on their surface bind factor Va and initiate assembly of the prothrombinase complex.</p><p>Patients with Scott syndrome have impaired thrombin generation, clinically prolonged bleeding, and a reduced tendency to form thromboses.</p><p class="headingAnchor" id="H15"><span class="h2">Extrinsic pathway</span></p><p class="headingAnchor" id="H603267846"><span class="h3">Tissue factor</span><span class="headingEndMark"> — </span>Vessel wall damage leads to expression of tissue factor (TF, tissue thromboplastin), an integral membrane glycoprotein [<a href="#rid55">55</a>]. Tissue factor is not normally expressed on vascular endothelial cells or monocytes but is constitutively expressed on certain biological surfaces, such as skin, organ surfaces, vascular adventitia, and many of their malignant counterparts. Normally, TF is exposed to blood flow only after endothelial damage [<a href="#rid56">56</a>]. The mechanism may be either via direct exposure of the subendothelial matrix and/or via cytokine- (especially interleukin [IL]-6-) induced expression of TF on activated monocytes and endothelial cells [<a href="#rid57">57</a>].</p><p>The majority of the TF is in a functionally inactive ("encrypted") state. Upon cell lysis or certain in vitro conditions, such as stimulation by calcium ionophore, TF will become activated ("de-encrypted") and support FVIIa binding and activation of factor X. The encrypted state may be due to a pair of free cysteine residues (Cys186 and Cys209) which would become linked into a disulfide bond upon cell perturbation, leading to an allosteric change in the conformation of TF resulting in its active de-encrypted state [<a href="#rid58">58,59</a>]. Protein disulfide isomerase (PDI), glutathione, and nitric oxide have all been implicated in mediating this process [<a href="#rid59">59</a>]. However, not all of the data are consistent and whether Cys186 and Cys209 are involved in the de-encryption of TF remains controversial [<a href="#rid60">60-62</a>].</p><p>TF may also circulate in the blood, associated with cell-derived membrane microvesicles as well as in a soluble, alternatively-spliced form [<a href="#rid63">63,64</a>]. These microvesicles derive from lipid rafts on the surface of stimulated monocytes/macrophages, and are capable of fusing with, and initiating coagulation on, activated platelets [<a href="#rid65">65</a>]. (See <a class="local">'White blood cell contributions'</a> below.)</p><p>In addition to assembling clotting reactions on their surface, platelets may also synthesize their own tissue factor in order to generate thrombin in a timely and spatially circumscribed process [<a href="#rid66">66</a>], although this has been called into question [<a href="#rid67">67</a>]. </p><p class="headingAnchor" id="H603267853"><span class="h3">Activation of factors VII, X, and IX</span><span class="headingEndMark"> — </span>TF serves as the cofactor required for the production of activated factor VII (FVIIa) [<a href="#rid68">68,69</a>]. The TF-FVIIa complex activates factors X [<a href="#rid41">41,42</a>] and IX [<a href="#rid44">44,45</a>]. Activation of factor X occurs at the Arg52-Ile53 peptide bond in the heavy chain of factor X, leading to the formation of the serine protease Xa [<a href="#rid43">43</a>]. Factor IXa in complex with its cofactor factor VIIIa also activates factor X (the intrinsic X-ase as noted above)  (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a>) [<a href="#rid42">42</a>].</p><p>This dual pathway of factor X activation (ie, directly and indirectly via activation of factor IX) is necessary because of the limited amount of TF generated in vivo and the presence of the tissue factor pathway inhibitor (TFPI) which, when complexed with factor Xa, inhibits the TF/FVIIa complex [<a href="#rid70">70</a>]. Thus, sustained generation of thrombin depends upon the activation of factor IX and its cofactor factor VIII. This process is amplified because factor VIII is activated by both factor Xa and thrombin [<a href="#rid41">41,71</a>] and factor IXa by thrombin-induced activation of factor XI [<a href="#rid72">72-76</a>]. As a result, there is a progressive increase in factor VIII and factor IX activation as factor Xa and thrombin are formed.</p><p>In vitro studies using human plasma have also demonstrated a feed-forward loop in which the TF/FVIIa complex can activate factor VIII, a component of the intrinsic (contact activation) pathway [<a href="#rid77">77</a>]. (See <a class="local">'Intrinsic or contact activation pathway'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h2">Intrinsic or contact activation pathway</span><span class="headingEndMark"> — </span>The initial phase of the intrinsic or contact activation pathway consists of several plasma proteins including factor XII (Hageman factor), prekallikrein (Fletcher factor) and high molecular weight kininogen (HMWK, Fitzgerald factor). These factors are activated by contact with negatively charged surfaces, leading to the term "contact activation pathway." Contact with negatively charged surfaces initiates the following sequence:</p><p class="bulletIndent1"><span class="glyph">●</span>Enhanced auto-activation of factor XII. Activated factor XII (factor XIIa) in conjunction with HMWK activates factor XI, which in turn, activates factor IX.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Factor IXa in complex with factor VIIIa forms the intrinsic X-ase, leading to the formation of factor Xa (see <a class="local">'Multicomponent complexes'</a> above). Factor VIII is activated by both factor Xa and thrombin [<a href="#rid41">41,71</a>]. Thus, there is a progressive increase in factor VIII activation as factor Xa and thrombin are formed. Thrombin also increases the generation of factor IXa via the activation of factor XI [<a href="#rid72">72,73,75,76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Factor XIIa activates plasma prekallikrein (PPK) to plasma kallikrein (PK), which liberates bradykinin (BK) from HMWK. BK is a major inflammatory peptide that induces pain and vasodilation (see <a class="local">'Blood coagulation as part of the host defense system'</a> below). PK also activates factor XII, thus forming a positive feedback loop of activation [<a href="#rid78">78</a>].</p><p></p><p>The remainder of the intrinsic pathway uses the same cascade as the extrinsic pathway (the common pathway), which involves factors V, prothrombin, and fibrinogen.</p><p>As noted above, in vitro studies suggest that this pathway can also be activated by the TF/FVIIa complex. (See <a class="local">'Extrinsic pathway'</a> above.)</p><p class="headingAnchor" id="H349234200"><span class="h3">Critical role of polyphosphate in initiating blood clotting via the intrinsic contact pathway</span><span class="headingEndMark"> — </span>Inorganic polyphosphate (polyP) is a linear highly anionic polymer of orthophosphates linked by high-energy phosphoanhydride bonds. It is ubiquitous in biology and can vary from a few to several thousand phosphate units in polymer length, depending on the organisms and tissues from which it is derived. In microorganisms, polyP is synthesized from ATP and may serve as an energy store allowing the bacteria to resynthesize ATP in times of starvation [<a href="#rid79">79</a>]. PolyP is also stored in human platelet dense granules and is efficiently released upon platelet activation [<a href="#rid80">80</a>]. In contrast to microbial polyP, platelet polyP is smaller, consisting of 60 to 100 phosphate units.</p><p>With its multiple anionic charges, polyP is a potent procoagulant, and it likely represents the "physiological" or "pathological" negatively charged surface that triggers blood coagulation via the intrinsic pathway. The source of polyP in this setting may derive from injured tissues at the wound site or a microbial source in the case of an infection. In addition to triggering intrinsic pathway activation, polyP has other effects on blood clotting. It accelerates factor V and factor XI activation by thrombin, abrogates the inhibitory effect of tissue factor pathway inhibitor (TFPI), and enhances fibrin polymerization (making the fibrils thicker). </p><p>The potency of polyP is dependent on its chain length. Long-chain polyP (from a microbial source) is efficient in carrying out all four functions, while medium-size polyP (from platelets) is less effective in triggering the intrinsic pathway but effective in accelerating blood clotting once it is initiated [<a href="#rid81">81</a>].</p><p>Compounds that inhibit polyphosphate are under investigation as anticoagulants. (See  <a class="medical medical_review" href="/z/d/html/138700.html" rel="external">"Investigational anticoagulants", section on 'Polyphosphate inhibitors'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Deficiencies of intrinsic contact pathway proteins</span><span class="headingEndMark"> — </span>The physiologic relevance of the initial complex of the intrinsic contact pathway is not fully established. Deficiencies in these proteins (prekallikrein, HMWK, and factor XII) are not associated with bleeding tendencies, suggesting that the initiation portion of the intrinsic pathway (the contact phase) is not very important in vivo [<a href="#rid82">82,83</a>].</p><p>Mutations in factor XII have been seen in a subset of patients with hereditary angioedema (HAE) and normal C1 inhibitor levels, an autosomal dominant disease characterized by recurrent attacks of upper respiratory tract edema, although the bleeding phenomena and coagulation defects in these patients have not been well characterized. (See  <a class="medical medical_review" href="/z/d/html/16529.html" rel="external">"Hereditary angioedema with normal C1 inhibitor"</a>.)</p><p>However, injury-related bleeding is seen with deficiency of factor XI [<a href="#rid84">84</a>], suggesting that factor XI plays an important hemostatic role, independent of contact activation and factor XII. One likely mechanism is that thrombin feedback activates factor XI, with polyP, released from activated platelets or derived from injured tissues, serving as a cofactor [<a href="#rid72">72-74,85</a>]. Factor XIa then activates factor IX, which leads to further thrombin formation after the clot has been formed [<a href="#rid73">73</a>].</p><p>This interpretation is also consistent with the phenotype observed in mice deficient in either factor XII or factor XI. These mice do not exhibit any bleeding problems under normal circumstances, similar to patients deficient in factor XII or factor XI, but surprisingly, they are protected from arterial thrombosis in experimental thrombosis models [<a href="#rid86">86,87</a>]. In this regard, it is notable that patients severely deficient in factor XI (&lt;15 percent), are reported to be protected from ischemic stroke but not myocardial infarction [<a href="#rid88">88</a>]. Further evidence for the lack of spontaneous bleeding with factor XI deficiency comes from a trial in which antisense therapy was used to lower the activity of factor XI to approximately 20 percent of normal in patients undergoing knee replacement surgery; this was able to reduce the incidence of venous thrombosis without increasing bleeding [<a href="#rid89">89</a>]. Genetic polymorphisms of factor XII have also been linked to an increased incidence of thrombosis [<a href="#rid90">90-92</a>]. These data suggest that the additional thrombin generated via the tertiary amplification pathway, involving factor XII or factor XI, may play more of a role in pathological thrombosis rather than physiological hemostasis.</p><p>This mechanism also provides a rationale by which bleeding can occur in patients with factor XI deficiency: increased fibrinolysis due to diminished activation of thrombin-activatable fibrinolysis inhibitor (TAFI) [<a href="#rid73">73,93,94</a>]. The relatively high concentration of thrombin required within the clot for activation of TAFI appears to come from thrombin-mediated factor XI activation after the clot has been formed [<a href="#rid93">93</a>]. Thus, in the absence of factor XI, sufficient TAFI is not generated in order to protect the clot from lysis. (See  <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">"Factor XI (eleven) deficiency"</a> and <a class="local">'CPB2/TAFI'</a> below.)</p><p class="headingAnchor" id="H4210635"><span class="h2">Continuation of the coagulation cascade</span><span class="headingEndMark"> — </span>Once factor X has been activated, the coagulation pathway proceeds as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Factor V, released from platelet alpha granules during platelet activation and cleaved by thrombin to form activated factor V (factor Va), binds factor Xa [<a href="#rid95">95-98</a>]. Platelet factor V appears to be more important for assembly of the prothrombinase complex than circulating factor V [<a href="#rid99">99</a>]. Subsequent factor Va inactivation by activated protein C (aPC) and protein S is an important step in preventing excessive coagulation. (See <a class="local">'Activated protein C and protein S'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Factor Xa linked to factor Va on the platelet phospholipid surface forms the prothrombinase complex, which converts one molecule of prothrombin (factor II) to one molecule of its activated form, thrombin (factor IIa), with the concomitant release of the prothrombin activation fragment F1+2 (F1.2)  (<a class="graphic graphic_figure graphicRef97057" href="/z/d/graphic/97057.html" rel="external">figure 4</a>) [<a href="#rid100">100,101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombin converts fibrinogen to fibrin [<a href="#rid102">102</a>], which undergoes polymerization. (See  <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">"Disorders of fibrinogen", section on 'Biology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activated factor XIII (factor XIIIa) stabilizes and crosslinks overlapping fibrin stands [<a href="#rid103">103</a>]. Factor XIIIa (along with fibrinogen) also controls the volume of red blood cells (RBCs) trapped within a thrombus, which in turn controls clot size. Mice lacking factor XIII (or harboring a fibrinogen mutation that abrogates factor XIIIa binding) formed clots approximately one-fifth the size of those in wild type mice, due to extrusion of RBCs during clot retraction; similar findings were seen in the plasma from a factor XIII-deficient patient [<a href="#rid104">104</a>]. The formation of factor XIIIa is promoted by the complexing of thrombin, fibrin, and factor XIII [<a href="#rid105">105</a>].</p><p></p><p>As noted above, thrombin also accelerates the activation of factors XI and VIII, in addition to factor V [<a href="#rid41">41,71-74,96</a>]. Activated factor XI in turn activates factor IX. Thus, factor XI activation by thrombin may function as an adjunctive activation pathway, the absence of which may account for delayed bleeding episodes in factor XI deficient patients, usually in a postoperative setting. (See <a class="local">'CPB2/TAFI'</a> below.)</p><p class="headingAnchor" id="H18"><span class="h1">CONTROL MECHANISMS AND TERMINATION OF CLOTTING</span><span class="headingEndMark"> — </span>The interactions between activated platelets and the clotting cascade, with its built-in amplification, give rise to a hemostatic response that is rapid and localized to the injury site. It is also potentially explosive, and, if unchecked, could lead to thrombosis, vascular inflammation, and tissue damage. This does not usually happen because coagulation is modulated by a number of mechanisms: dilution of procoagulants in flowing blood, removal of activated factors through the reticuloendothelial system, especially in the liver, and control of the activated procoagulants and platelets by natural antithrombotic pathways [<a href="#rid1">1</a>]. Most of these antithrombotic pathways are anchored on vascular endothelial cells, which play a major and active role in maintaining the fluidity of blood  (<a class="graphic graphic_figure graphicRef111299" href="/z/d/graphic/111299.html" rel="external">figure 6</a>).</p><p>The physiologic (endogenous) inhibitors of the coagulation pathways are:</p><p class="bulletIndent1"><span class="glyph">●</span>Tissue factor pathway – tissue factor pathway inhibitor (TFPI)</p><p class="bulletIndent1"><span class="glyph">●</span>Contact activation pathway – C1 esterase inhibitor (C1-inh)</p><p></p><p class="headingAnchor" id="H4245430042"><span class="h2">Tissue factor pathway inhibitor</span><span class="headingEndMark"> — </span>TFPI circulates in plasma, but at very low concentrations, in contrast to AT [<a href="#rid106">106</a>]. TFPI is a Kunitz-type protease inhibitor. It inhibits factor X activation in two ways: it directly inhibits factor Xa; and it complexes with factor Xa and the TFPI-FXa complex inhibits TF/FVIIa, thereby regulating the triggering mechanism of the extrinsic pathway  (<a class="graphic graphic_figure graphicRef75450" href="/z/d/graphic/75450.html" rel="external">figure 5</a>) [<a href="#rid107">107-109</a>].</p><p>TFPI is primarily synthesized by the microvascular endothelium. TFPI circulates in plasma in a free form (TFPI-alpha) that accounts for 20 percent of total plasma TFPI and in a slightly truncated form in association with low-density lipoproteins that accounts for 80 percent of total plasma TFPI. The majority of TFPI remains associated with the endothelial surface (as TFPI-beta), bound to cell surface glycosaminoglycans [<a href="#rid110">110</a>]. The plasma concentration of TFPI is greatly increased following intravenous heparin administration; this release of endothelial TFPI may contribute to the antithrombotic effects of heparin and low-molecular-weight-heparin.</p><p><em>TFPI</em> gene disruption leads to intrauterine lethality in mice; TFPI deficiency has not been reported in humans [<a href="#rid111">111</a>]. Conversely, TFPI levels and activity are markedly increased in two inherited bleeding disorders involving factor V mutations (factor V Amsterdam and factor V East Texas) [<a href="#rid112">112-114</a>]. Both of these mutations lead to production of a truncated form of factor V via alternative splicing, and the factor V-short forms a complex with TFPI-alpha, leading to a 10-fold increase in circulating levels of TFPI-alpha. Individuals with these mutations manifest an autosomal dominant bleeding disorder. (See  <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">"Rare inherited coagulation disorders", section on 'Genetics'</a>.)</p><p>Recombinant TFPI is being evaluated for its potential role as an anticoagulant [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/z/d/html/138700.html" rel="external">"Investigational anticoagulants", section on 'Recombinant TFPI and anti-TF antibodies'</a>.)</p><p class="headingAnchor" id="H836658100"><span class="h2">C1 esterase inhibitor</span><span class="headingEndMark"> — </span>C1-inh is a member of the family of serine protease inhibitors (SERPINs). It is synthesized in the liver. C1-inh inhibits FXIIa and PK as well as the complement proteases C1r, C1s, and FXIa. Deficiency of C1-inh results in an angioedema syndrome known as C1INH-AAE; this is not a clinical hypercoagulable state. (See  <a class="medical medical_review" href="/z/d/html/8112.html" rel="external">"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8110.html" rel="external">"Acquired C1 inhibitor deficiency: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H4023873769"><span class="h2">Control of the termination phase of coagulation</span><span class="headingEndMark"> — </span>The regulation of the termination phase of the coagulation process involves another circulating serine protease inhibitor (SERPIN), antithrombin (previously called antithrombin III), and a clotting-initiated inhibitory process, the protein C pathway. In addition, prostacyclin, thromboxane, and nitric oxide (NO) modulate vascular and platelet reactivity.</p><p>This termination phase is critical in mediating the extent of clot formation, as demonstrated by the thrombotic disorders present in individuals with deficiencies in these pathways and bleeding disorders in individuals with activating mutations. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Deficiencies of antithrombin, protein C, and protein S. (See  <a class="medical medical_review" href="/z/d/html/1360.html" rel="external">"Antithrombin deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">"Protein C deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/1357.html" rel="external">"Protein S deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activating mutations in factor V and thrombomodulin. (See  <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">"Rare inherited coagulation disorders"</a> and  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a> and <a class="local">'Activated protein C and protein S'</a> below and <a class="local">'Tissue factor pathway inhibitor'</a> above.)</p><p></p><p class="headingAnchor" id="H7461698"><span class="h2">White blood cell contributions</span><span class="headingEndMark"> — </span>Activated macrophages and monocytes are able to express tissue factor (TF) on their surfaces or within microparticles, which contributes to physiologic hemostasis as well as pathologic thrombosis [<a href="#rid116">116</a>]. Regulation of TF messenger RNA levels by a poly(adenosine 5’-diphposphate [ADP]-ribose) polymerase (PARP) protein, PARP-14, may prevent excessive thrombosis during periods of inflammation [<a href="#rid117">117</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Antithrombin, heparin, and heparan</span><span class="headingEndMark"> — </span>Antithrombin (AT) is a circulating serine protease inhibitor (SERPIN). It neutralizes most of the enzymes in the clotting cascade, especially thrombin (factor IIa), factors Xa, and IXa; as well as factor XIIa and factor XIa, by forming equimolar, irreversible complexes with them [<a href="#rid118">118</a>]. AT has two active functional sites, the reactive center, Arg393-Ser394, and the heparin binding site located at the amino terminus of the protein [<a href="#rid118">118</a>].</p><p>The role of AT is enhanced by endogenous heparan sulfate (a glycosaminoglycan found on endothelial surfaces), which contain a pentasaccharide sequence that mediates its binding to AT [<a href="#rid119">119-121</a>]. The binding of endogenous (or exogenous) heparins to the heparin binding site on AT produces a conformational change in AT, thus "activating" it and accelerating its inactivation of clotting factors by 1000 to 4000-fold  (<a class="graphic graphic_figure graphicRef101832" href="/z/d/graphic/101832.html" rel="external">figure 7</a>) [<a href="#rid118">118,119</a>]. <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a>, a form of low-molecular-weight heparin, is the pharmacologic version of this pentasaccharide sequence. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Mechanisms of action'</a> and  <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects", section on 'Mechanism of action'</a>.)</p><p>The entire luminal surface of the vascular system is covered by endothelial cells that are coated with activated AT and poised to rapidly inactivate any excess thrombin in the general circulation  (<a class="graphic graphic_figure graphicRef111299" href="/z/d/graphic/111299.html" rel="external">figure 6</a>). The potential of this system is magnified by the surface-to-volume geometry of the microcirculation, in which 1 mL of blood can be exposed to as much as 5000 cm<sup>2</sup> of endothelial surface.</p><p class="headingAnchor" id="H20"><span class="h2">Activated protein C and protein S</span><span class="headingEndMark"> — </span>As clot formation progresses, thrombin (factor IIa) binds to thrombomodulin (TM), an integral membrane protein on the endothelial cell surface  (<a class="graphic graphic_figure graphicRef111299" href="/z/d/graphic/111299.html" rel="external">figure 6</a>) [<a href="#rid122">122</a>].</p><p>Binding of thrombin to TM induces a drastic change in thrombin substrate specificity such that it loses all of its procoagulant functions (eg, platelet activation, fibrin clot formation) and instead acquires the ability to activate protein C  (<a class="graphic graphic_figure graphicRef110320" href="/z/d/graphic/110320.html" rel="external">figure 8</a>) [<a href="#rid123">123-125</a>]. Thus, binding to TM functions like a molecular switch, transforming thrombin from a procoagulant to an anticoagulant via its activation of protein C. This remarkable transformation is not due to a conformational change in thrombin's active site, as initially proposed, but rather due to the binding of TM to the exosite I of thrombin, the major docking site for thrombin's procoagulant substrates, and preventing them from binding to thrombin [<a href="#rid126">126</a>]. On the other hand, protein C binds to TM complexed with thrombin, allowing it to be cleaved to become activated. This activation step is enhanced by an endothelial receptor for protein C (EPCR) [<a href="#rid127">127-129</a>]. As a testament to this TM-induced change of function for thrombin, a knockout mouse model in which the TM gene was ablated was associated with unfettered activation of the coagulation system and widespread thrombosis [<a href="#rid130">130</a>]. Conversely, a naturally-occurring TM mutation (C1611A) that causes TM to be shed from the endothelial surface and circulate at very high levels in the plasma is associated with a bleeding phenotype. (See  <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">"Rare inherited coagulation disorders", section on 'Genetics'</a>.)</p><p>Activated protein C (aPC), in association with protein S on phospholipid surfaces, proteolytically inactivates factors Va and VIIIa, thereby inactivating the prothrombinase and the intrinsic X-ase, respectively [<a href="#rid131">131-134</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Factor Va is first cleaved at Arg506 and then at Arg306 and Arg679 by aPC. The peptide bond cleavage at Arg506 is essential for the exposure of cleavage sites at Arg306 and Arg679 [<a href="#rid132">132</a>].</p><p></p><p class="bulletIndent1">Factor V Leiden, in which the arginine at position 506 is replaced by glutamine, is not susceptible to cleavage at position 506 by aPC and is therefore inactivated more slowly, resulting in a hypercoagulable state. (See  <a class="medical medical_review" href="/z/d/html/1355.html" rel="external">"Factor V Leiden and activated protein C resistance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Factor V cleaved at position 506 is also thought to be a cofactor, along with protein S, in supporting the role of aPC in the degradation of factors Va and VIIIa [<a href="#rid135">135</a>]. Thus, lack of this cleavage product decreases the anticoagulant activity of aPC, further increasing the hypercoagulable state in patients with factor V Leiden [<a href="#rid136">136</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Factor VIIIa is first cleaved at Arg336 and then Arg562 by aPC [<a href="#rid134">134</a>]. The rate of aPC-mediated inactivation is increased several fold by protein S, an effect that is impaired by factor IXa.</p><p></p><p>Protein S circulates in two forms. In the free form, it is active as an anticoagulant; in the bound form, it is complexed to C4b binding protein of the complement system and is functionally inactive. C4b binding protein is an acute-phase reactant that increases in concentration in inflammatory states; as a result, the activity of free protein S is reduced in these conditions, enhancing the likelihood of thrombosis.</p><p class="headingAnchor" id="H22"><span class="h2">Prostacyclin and thromboxane</span><span class="headingEndMark"> — </span>Intact endothelial cells in proximity to disrupted endothelium release arachidonic acid from cell membrane phospholipids by phospholipase A2. The enzyme cyclooxygenase-1 (COX-1 or prostaglandin endoperoxide H synthase-1) converts arachidonic acid into thromboxane A2 (TxA2) in platelets, while prostacyclin (PGI2), a dominant product of the endothelium, appears to largely derive from COX-2, the production of which is induced by laminar blood flow under physiologic conditions [<a href="#rid137">137,138</a>].</p><p>TxA2 is a potent stimulator of platelet aggregation and produces vasoconstriction, while PGI2, via activation of adenylate cyclase, blocks platelet aggregation and antagonizes TxA2-mediated vasoconstriction [<a href="#rid139">139</a>]. (See  <a class="medical medical_review" href="/z/d/html/7989.html" rel="external">"NSAIDs (including aspirin): Pharmacology and mechanism of action", section on 'Cyclooxygenase enzymes'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Low dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> irreversibly acetylates and inhibits COX-1 and only weakly inhibits COX-2 [<a href="#rid140">140</a>]. Since platelets cannot make new COX-1, the inhibition of TxA2 is permanent for the life of the platelet.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In comparison, endothelial cells can make new COX-1 as well as COX-2 and higher doses of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> are required for inhibition of PGI2 production [<a href="#rid141">141</a>].</p><p></p><p>This distinction underlies the hypothesized mechanism for the benefit of low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in cardiovascular disease, as well as the increased cardiac toxicity of the selective COX-2 inhibitors. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Nitric oxide</span><span class="headingEndMark"> — </span>Nitric oxide (NO) (also known as endothelium-derived relaxing factor, EDRF) is formed from L-arginine in endothelial cells, catalyzed by the enzyme nitric oxide synthase (NOS)  (<a class="graphic graphic_figure graphicRef79786" href="/z/d/graphic/79786.html" rel="external">figure 9</a>). Acting through soluble guanylate cyclase in the vascular smooth muscle cells with the production of cGMP, it causes vasodilatation. NO also inhibits platelet adhesion and aggregation [<a href="#rid142">142</a>].</p><p>Platelets are also capable of synthesizing NO, with enhanced production in the setting of platelet adhesion to fibrillar collagen under shear flow [<a href="#rid143">143</a>]. This may provide negative feedback to limit excessive platelet adhesion and vasoconstriction at sites of vessel injury.</p><p>NO diffuses freely across cellular membranes and is rapidly destroyed by hemoglobin in nearby red blood cells; it therefore functions as a local (paracrine) hormone with a very short half-life. Release of free hemoglobin into the circulation (eg, during intravascular hemolysis) causes greater local depletion of NO.</p><p>Intravenous infusion of an arginine analog that blocks NO production leads to an immediate and substantial rise in blood pressure, suggesting that there is a continual, basal release of NO to regulate vascular tone [<a href="#rid144">144</a>].</p><p>Release of NO by endothelial cells can be upregulated (eg, by exercise) and downregulated (eg, by oxidative stress, smoking, and oxidized low-density lipoprotein [LDL]). NO levels are also reduced with aging and in the course of vascular disease (eg, diabetes and hypertension) as part of the manifestation of endothelial dysfunction [<a href="#rid145">145</a>].</p><p class="headingAnchor" id="H24"><span class="h1">CLOT DISSOLUTION AND FIBRINOLYSIS</span><span class="headingEndMark"> — </span>To restore vessel patency following hemostasis, the clot must be organized and removed by the proteolytic enzyme plasmin in conjunction with wound healing and tissue remodeling.</p><p class="headingAnchor" id="H597116"><span class="h2">Plasmin</span><span class="headingEndMark"> — </span>Plasminogen, the precursor molecule to plasmin, binds fibrin and tissue plasminogen activator (tPA). This ternary complex leads to conversion of the proenzyme plasminogen to active, proteolytic plasmin [<a href="#rid146">146,147</a>].</p><p>Plasmin has broad substrate specificity and, in addition to fibrin, cleaves fibrinogen and a variety of plasma proteins and clotting factors [<a href="#rid148">148</a>]. Plasmin cleaves the polymerized fibrin strand at multiple sites and releases fibrin degradation products (FDPs). One of the major FDPs is D-dimer, which consists of two D domains from adjacent fibrin monomers that have been crosslinked by activated factor XIII  (<a class="graphic graphic_figure graphicRef62012" href="/z/d/graphic/62012.html" rel="external">figure 10</a>). Plasmin also cleaves factor XIIIa, but not factor XIII, leading to reduced fibrin crosslinking [<a href="#rid149">149</a>].</p><p>The plasminogen/plasminogen-activator system is complex, paralleling the coagulation cascade  (<a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">figure 3</a>) [<a href="#rid150">150</a>]. Plasmin activity is regulated by vascular endothelial cells that secrete both serine protease plasminogen activators (tissue-type plasminogen activator and urokinase-type plasminogen activator) and plasminogen activator inhibitors (PAI-1 and PAI-2). (See  <a class="medical medical_review" href="/z/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis"</a>.)</p><p>Plasminogen deficiency (PLGD) is a rare disorder that presents with poor wound healing and formation of pseudomembranes in the eye, nose, mouth, respiratory, gastrointestinal, and genitourinary systems. (See  <a class="medical medical_review" href="/z/d/html/132290.html" rel="external">"Plasminogen deficiency"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Tissue-type plasminogen activator</span><span class="headingEndMark"> — </span>The tPA molecule is predominantly an endothelial cell enzyme. Its release is stimulated by a variety of substances including thrombin, serotonin, bradykinin, cytokines, and <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid151">151,152</a>]. In plasma it circulates as a complex with its natural inhibitor PAI-1 and is rapidly cleared by the liver.</p><p>Analogous to the prothrombin complex, the rapid generation of plasmin by tPA optimally takes place on a surface, the fibrin clot. Both tPA and fibrinogen bind to fibrin via recognition of lysine residues in the fibrin clot. When bound to fibrin, the binding interaction aligns tPA and plasminogen on the fibrin surface [<a href="#rid153">153</a>] so that the catalytic efficiency of tPA is increased several hundred-fold [<a href="#rid147">147</a>].</p><p class="headingAnchor" id="H26"><span class="h2">Urokinase</span><span class="headingEndMark"> — </span>Urokinase is the second physiologic plasminogen activator. It is present in high concentration in the urine. While tPA is largely responsible for initiating intravascular fibrinolysis, urokinase is the major activator of fibrinolysis in the extravascular compartment. Urokinase is secreted by many cell types in the form of prourokinase, also termed single-chain urokinase-type plasminogen activator (scu-PA). Prourokinase is converted to urokinase by plasmin; it has a low level of proteolytic activity unless it is exposed to fibrin.</p><p class="headingAnchor" id="H27"><span class="h2">Plasminogen activator inhibitors and alpha-2-antiplasmin</span><span class="headingEndMark"> — </span>The PAIs inhibit tPA [<a href="#rid154">154,155</a>], while alpha-2-antiplasmin inhibits plasmin [<a href="#rid156">156</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>PAI-1 is synthesized by endothelial cells and platelets which regulate its release during fibrinolysis. Patients deficient in PAI-1 have a bleeding diathesis usually related to trauma or surgery [<a href="#rid157">157,158</a>]. The release of PAI-1 by activated platelets may contribute to the relative resistance of platelet-rich arterial thrombi to thrombolysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PAI-2 is synthesized by white blood cells and the placenta and its levels are greatly increased during pregnancy. PAI-2 is less effective as a plasminogen inhibitor [<a href="#rid159">159</a>] and its biologic importance is uncertain.</p><p></p><p>Alpha-2-antiplasmin is secreted by the liver and is also present within platelets [<a href="#rid160">160</a>]. It can be crosslinked into the fibrin clot by factor XIIIa, and plays an important role in making thrombi resistant to plasmin by complexing with it. Plasmin released into the circulation is rapidly inactivated by alpha-2-antiplasmin. However, alpha-2-antiplasmin is present in lower concentrations than is plasminogen and therefore can become depleted while plasmin is continuing to be generated.</p><p class="headingAnchor" id="H28"><span class="h2">CPB2/TAFI</span><span class="headingEndMark"> — </span>When fibrin is degraded by plasmin, new carboxy-terminal lysines are exposed in the partially digested clot. These residues provide additional sites for plasminogen and tPA incorporation into the clot, generating additional plasmin, creating a positive feedback loop in clot lysis. </p><p>The exposed carboxy-terminal lysines on partially degraded fibrin are susceptible to removal by carboxypeptidases specific for basic residues [<a href="#rid161">161,162</a>]. One circulating basic carboxypeptidase (carboxypeptidase N) is constitutively active; another carboxypeptidase (carboxypeptidase B2) circulates as an inactive precursor (pro-CPB2) and is activated by the thrombin-thrombomodulin (TM) complex on the endothelial cell surface. </p><p>Similar to protein C, the activation of pro-CPB2 by the thrombin-TM complex is approximately 1000-fold faster than with free thrombin alone [<a href="#rid163">163,164</a>].</p><p>By cleaving C-terminal lysines from partially digested fibrin, CPB2 diminishes the incorporation and activation of plasminogen, leading to delayed clot lysis and protection of the clot from complete dissolution. Thus, CPB2 is also known as thrombin activatable fibrinolysis inhibitor (TAFI). It is notable that CPB2/TAFI also inactivates activated complement components C3a and C5a, thus playing a homeostatic role to limit inflammation [<a href="#rid165">165</a>]. (See <a class="local">'Blood coagulation as part of the host defense system'</a> below.)</p><p>Factor XIIIa may crosslink CPB2/TAFI to fibrin, helping to protect the newly formed fibrin from premature plasmin degradation. Crosslinking may also facilitate the activation of pro-CPB2/TAFI, stabilize enzymatic activity, and protect the active enzyme from further degradation [<a href="#rid166">166</a>].</p><p>From a physiologic standpoint, one can envisage that upon thrombin binding to TM, the thrombin-TM complex will activate protein C to dampen the clotting cascade, and will also activate pro-CPB2/TAFI, thereby protecting the clot already formed at the vascular wound from premature degradation. The concentration of thrombin required for the activation of pro-CPB2/TAFI is substantially higher than that for fibrinogen clotting. Thus, CPB2/TAFI activation requires amplification and acceleration of thrombin generation through feedback activation of factors V, VIII, and XI by the small amount of initially generated thrombin  (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a>).</p><p>This requirement for adequate activation of pro-CPB2/TAFI can have important clinical consequences in a number of acquired and congenital disorders of coagulation:</p><p class="bulletIndent1"><span class="glyph">●</span>The bleeding diathesis encountered in people with hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency) may be partly related to suboptimal activation of pro-CPB2/TAFI, leading to enhanced and premature clot lysis  (<a class="graphic graphic_figure graphicRef62974" href="/z/d/graphic/62974.html" rel="external">figure 11</a>) [<a href="#rid93">93,94,167-170</a>]. (See  <a class="medical medical_review" href="/z/d/html/1311.html" rel="external">"Genetics of hemophilia A and B", section on 'Role of factors VIII and IX in hemostasis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The low levels of pro-CPB2/TAFI seen in patients with chronic liver disease may be responsible, in part, for the low-grade fibrinolysis seen in this condition [<a href="#rid171">171</a>]. (See  <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Altered fibrinolytic system'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enhanced thrombin generation in patients with the G20210A prothrombin gene mutation may lead to increased activation of pro-CPB2/TAFI, resulting in inhibition of fibrinolysis and increased thrombotic risk [<a href="#rid172">172</a>]. (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A"</a>.)</p><p></p><p class="headingAnchor" id="H870573531"><span class="h1">DIFFERENCES IN BLOOD CLOTTING IN VEINS VERSUS ARTERIES</span><span class="headingEndMark"> — </span>Blood flow has a profound effect on blood clot formation. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>High flow (arterial)</strong> – Under high blood flow, as in the arterial system, assembly of the clotting cascade can only occur on activated platelet surface. (See <a class="local">'Procoagulant activity'</a> above.)</p><p></p><p class="bulletIndent1">Thus, an arterial blood clot is platelet-rich and fibrin-poor, sometimes referred to as a "white clot." </p><p></p><p class="bulletIndent1"><strong>Low flow (venous</strong>) – A venous blood clot, formed under much lower blood flow conditions, is platelet-poor and fibrin-rich. With the resultant entrapped red blood cells, this type of clot is referred to as a "red clot." </p><p></p><p class="bulletIndent1">This marked difference between the compositions of arterial and venous blood clots also accounts for the therapeutic efficacy of antiplatelet agents in the treatment of arterial thrombosis, while anticoagulants are effective in the treatment of venous thrombosis and much less so in treating arterial thrombosis. </p><p></p><p class="headingAnchor" id="H269250183"><span class="h1">BLOOD COAGULATION AS PART OF THE HOST DEFENSE SYSTEM</span><span class="headingEndMark"> — </span>Interactions between coagulation factors and the immune system have been identified at several stages of the hemostatic process. These interactions are complex and include contributions of hemostatic factors to host defense as well as effects of immune mediators on hemostasis [<a href="#rid173">173-175</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Platelets may be capable of killing microorganisms. In a series of blood samples from individuals living in malaria-endemic areas, platelets were shown to bind to several plasmodial species within red blood cells and to kill the parasites [<a href="#rid176">176</a>]. An in vitro assay demonstrated that parasite killing was dependent on platelet factor 4.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activated protein C (aPC), in addition to its well-established anticoagulant role in inhibiting activated factor V (FVa) and FVIIIa, also has cellular cytoprotective effects. This is dependent on aPC binding to endothelial protein C receptor (EPCR). EPCR-bound aPC (but not free aPC) cleaves endothelial protease activated receptor (PAR)-1, resulting in cell signaling and the initiation of a cell protective program that includes antiinflammatory and anti-apoptotic activities and stabilization of endothelial barriers to prevent vascular leakage [<a href="#rid177">177</a>]. The finding that this cytoprotective effect of aPC is dependent on cleavage of PAR-1 is surprising and puzzling since thrombin cleavage of endothelial PAR-1 leads to a prothrombotic phenotype and disrupts the endothelial barrier integrity, the opposite of the aPC/EPCR-PAR-1 signaling effect. The mechanisms for this remarkable change in signaling profile are under investigation. The aPC/EPCR-PAR-1 signaling may involve different coupling with other G protein-coupled receptors (GPCRs) [<a href="#rid177">177</a>]. There is also evidence that aPC/EPCR cleaves PAR-1 at Arg46 rather than a Arg41 (which is cleaved by thrombin), resulting in a different signaling program from that of thrombin [<a href="#rid178">178</a>].</p><p></p><p class="bulletIndent1">The role of carboxypeptidase B2 (CPB2) is also not limited to dampening fibrinolysis. CPB2 can inactivate activated complement components C3a and C5a, the major anaphylatoxins resulting from complement activation, and bradykinin (BK), potent inflammatory mediators found at sites of inflammation; inactivation is achieved by removing the carboxy-terminal arginine residue from these inflammatory mediators [<a href="#rid179">179</a>].</p><p></p><p class="bulletIndent1">Thus the activation of protein C and pro-CPB2 by the thrombin-TM complex on endothelial cells may serve as a negative homeostatic mechanism to down-regulate thrombin's inflammatory activities in the cross-talk between coagulation, inflammation, and innate immunity [<a href="#rid180">180</a>]. (See <a class="local">'Thrombin generation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory mediators may alter the normal thromboresistant phenotype of vascular endothelial cells, and proinflammatory cytokines can induce the expression of tissue factor on a number of surfaces [<a href="#rid181">181</a>]. (See  <a class="medical medical_review" href="/z/d/html/1330.html" rel="external">"The endothelium: A primer", section on 'Procoagulant properties'</a> and <a class="local">'Tissue factor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monocytes and neutrophils are recruited to the vessel wall and incorporated into the growing clot [<a href="#rid175">175</a>]. When pathogen-associated molecular patterns or damage associated molecular patterns (PAMPs or DAMPs) are recognized by monocytes, the monocytes may deliver tissue factor to sites of pathogen exposure. Neutrophil extracellular traps (NETs) can activate factor XII and bind von Willebrand factor, leading to platelet recruitment. (See  <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">"An overview of the innate immune system", section on 'Microbial detection through pattern recognition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deposition of fibrin at sites of infection prevents the dissemination of microorganisms from the initial site of inoculation. Virulence factors in bacteria such as <em>Yersinia </em>and <em>Streptococcus</em> have been identified as bacterial plasminogen activators that exploit the host's plasmin-mediated fibrinolysis process to support microbial dissemination [<a href="#rid182">182</a>]. (See <a class="local">'Continuation of the coagulation cascade'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The complement protein C4b, an acute phase reactant, sequesters protein S. Thus, in infections and inflammatory states, free protein S is reduced, shifting the hemostatic balance toward clotting. Factor V appears to have a role in inflammation that is independent of its proteolytic activity against factors Va and VIIIa [<a href="#rid183">183</a>]. (See <a class="local">'Activated protein C and protein S'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excessive activation of the alternative pathway of complement, due to mutations or autoantibodies affecting complement regulators or effectors, can cause a thrombotic microangiopathy (TMA) associated with microvascular thrombosis. (See  <a class="medical medical_review" href="/z/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)", section on 'Complement-mediated TMA pathogenesis'</a>.)</p><p></p><p class="headingAnchor" id="H19117173"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phases of coagulation and fibrinolysis</strong> – When the pathways of clot formation and clot lysis are appropriately linked, a clot is laid down initially to stop bleeding, followed later by clot lysis and tissue remodeling  (<a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">figure 3</a>). Abnormal bleeding can result from diminished clot generation or enhanced clot lysis, while excessive clot formation or reduced clot lysis can lead to excessive thrombosis. The following phases coordinate this overall process. (See <a class="local">'Phases of the hemostatic process'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Platelet plug</strong> – Platelets are activated at the site of vascular injury to form a platelet plug that provides the initial hemostatic response, including exposure of procoagulant phospholipids on the platelet surface and the assembly of components of the clotting cascade. (See <a class="local">'Formation of the platelet plug'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibrin deposition</strong> – Generation or exposure of tissue factor at the wound site, its interaction with factor VIIa and the subsequent generation of activated factor X, are the primary physiologic events in initiating clotting, while components of the intrinsic pathway (ie, factors VIII, IX, XI) are responsible for amplification of this process. (See <a class="local">'Clotting cascade and propagation of the clot'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Termination</strong> – The termination phase of coagulation involves antithrombin, tissue factor pathway inhibitor and the protein C pathway  (<a class="graphic graphic_figure graphicRef111299" href="/z/d/graphic/111299.html" rel="external">figure 6</a>). This phase is critical in mediating the extent of clot formation, as demonstrated by the thrombotic disorders present in individuals with abnormalities in this pathway. (See <a class="local">'Control mechanisms and termination of clotting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibrinolysis </strong>– To restore vessel patency, the clot must be organized and removed. Plasminogen and tissue plasminogen activator (tPA) bind to fibrin and tPA converts plasminogen to active, proteolytic plasmin, which cleaves fibrin, fibrinogen, and a variety of plasma proteins and clotting factors. The plasminogen/plasminogen-activator system is complex, paralleling the coagulation cascade  (<a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">figure 3</a>). (See <a class="local">'Clot dissolution and fibrinolysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of clot location and blood flow</strong> – The site of clot formation (artery or vein) and the rate of blood flow have important effects on clot composition. These differences may explain the differential efficacy of anticoagulation for venous thrombosis and anti-platelet agents for arterial thrombosis. (See <a class="local">'DIfferences in blood clotting in veins versus arteries'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Connections to the immune system</strong> – Several connections have been identified between the hemostatic system and the immune system. (See <a class="local">'Blood coagulation as part of the host defense system'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106:2605.</a></li><li><a class="nounderline abstract_t">Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359:938.</a></li><li><a class="nounderline abstract_t">Shen J, Sampietro S, Wu J, et al. Coordination of platelet agonist signaling during the hemostatic response in vivo. Blood Adv 2017; 1:2767.</a></li><li><a class="nounderline abstract_t">Watson SP. Collagen receptor signaling in platelets and megakaryocytes. Thromb Haemost 1999; 82:365.</a></li><li><a class="nounderline abstract_t">Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3:1800.</a></li><li><a class="nounderline abstract_t">Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407:258.</a></li><li><a class="nounderline abstract_t">Brass LF. Thrombin and platelet activation. Chest 2003; 124:18S.</a></li><li><a class="nounderline abstract_t">Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006; 114:1070.</a></li><li><a class="nounderline abstract_t">Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394:690.</a></li><li><a class="nounderline abstract_t">Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366:1404.</a></li><li><a class="nounderline abstract_t">Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366:20.</a></li><li><a class="nounderline abstract_t">Magnani G, Bonaca MP, Braunwald E, et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc 2015; 4:e001505.</a></li><li><a class="nounderline abstract_t">Dubois C, Panicot-Dubois L, Gainor JF, et al. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 2007; 117:953.</a></li><li><a class="nounderline abstract_t">Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409:202.</a></li><li><a class="nounderline abstract_t">Clemetson KJ. Platelet GPIb-V-IX complex. Thromb Haemost 1997; 78:266.</a></li><li><a class="nounderline abstract_t">Andrews RK, Berndt MC. Bernard-Soulier syndrome: an update. Semin Thromb Hemost 2013; 39:656.</a></li><li><a class="nounderline abstract_t">Sixma JJ, van Zanten GH, Huizinga EG, et al. Platelet adhesion to collagen: an update. Thromb Haemost 1997; 78:434.</a></li><li><a class="nounderline abstract_t">Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84:289.</a></li><li><a class="nounderline abstract_t">Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64:1393.</a></li><li><a class="nounderline abstract_t">Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267:11300.</a></li><li><a class="nounderline abstract_t">Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91:2645.</a></li><li><a class="nounderline abstract_t">Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008; 112:3011.</a></li><li><a class="nounderline abstract_t">Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103:229.</a></li><li><a class="nounderline abstract_t">Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989; 74:1181.</a></li><li><a class="nounderline abstract_t">Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98:1164.</a></li><li><a class="nounderline abstract_t">Harrison P, Savidge GF, Cramer EM. The origin and physiological relevance of alpha-granule adhesive proteins. Br J Haematol 1990; 74:125.</a></li><li><a class="nounderline abstract_t">Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008; 359:1261.</a></li><li><a class="nounderline abstract_t">Reinhardt C, von Brühl ML, Manukyan D, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008; 118:1110.</a></li><li><a class="nounderline abstract_t">Cho J, Furie BC, Coughlin SR, Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest 2008; 118:1123.</a></li><li><a class="nounderline abstract_t">Kojima H, Newton-Nash D, Weiss HJ, et al. Production and characterization of transformed B-lymphocytes expressing the membrane defect of Scott syndrome. J Clin Invest 1994; 94:2237.</a></li><li><a class="nounderline abstract_t">Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22:1381.</a></li><li><a class="nounderline abstract_t">Pan J, Dinh TT, Rajaraman A, et al. Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. Blood 2016; 128:104.</a></li><li><a class="nounderline abstract_t">Fahs SA, Hille MT, Shi Q, et al. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 2014; 123:3706.</a></li><li><a class="nounderline abstract_t">Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood 2014; 123:3697.</a></li><li><a class="nounderline abstract_t">Hansson K, Stenflo J. Post-translational modifications in proteins involved in blood coagulation. J Thromb Haemost 2005; 3:2633.</a></li><li><a class="nounderline abstract_t">Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 1999; 93:1798.</a></li><li><a class="nounderline abstract_t">Rapaport SI, Rao LV. The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemost 1995; 74:7.</a></li><li><a class="nounderline abstract_t">Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol Dis 2006; 36:108.</a></li><li><a class="nounderline abstract_t">Camire RM, Bos MH. The molecular basis of factor V and VIII procofactor activation. J Thromb Haemost 2009; 7:1951.</a></li><li><a class="nounderline abstract_t">Ivanciu L, Krishnaswamy S, Camire RM. New insights into the spatiotemporal localization of prothrombinase in vivo. Blood 2014; 124:1705.</a></li><li><a class="nounderline abstract_t">Butenas S, van 't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272:21527.</a></li><li><a class="nounderline abstract_t">Jesty J, Spencer AK, Nemerson Y. The mechanism of activation of factor X. Kinetic control of alternative pathways leading to the formation of activated factor X. J Biol Chem 1974; 249:5614.</a></li><li><a class="nounderline abstract_t">Baugh RJ, Krishnaswamy S. Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex. J Biol Chem 1996; 271:16126.</a></li><li><a class="nounderline abstract_t">Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977; 74:5260.</a></li><li><a class="nounderline abstract_t">Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63:1338.</a></li><li><a class="nounderline abstract_t">Rosing J, van Rijn JL, Bevers EM, et al. The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65:319.</a></li><li><a class="nounderline abstract_t">Ruben EA, Summers B, Rau MJ, et al. Cryo-EM structure of the prothrombin-prothrombinase complex. Blood 2022; 139:3463.</a></li><li><a class="nounderline abstract_t">Esmon CT. The endothelial protein C receptor. Curr Opin Hematol 2006; 13:382.</a></li><li><a class="nounderline abstract_t">Krishnaswamy S. The transition of prothrombin to thrombin. J Thromb Haemost 2013; 11 Suppl 1:265.</a></li><li><a class="nounderline abstract_t">Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264:17049.</a></li><li><a class="nounderline abstract_t">Toti F, Satta N, Fressinaud E, et al. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996; 87:1409.</a></li><li><a class="nounderline abstract_t">Zhou Q, Sims PJ, Wiedmer T. Expression of proteins controlling transbilayer movement of plasma membrane phospholipids in the B lymphocytes from a patient with Scott syndrome. Blood 1998; 92:1707.</a></li><li><a class="nounderline abstract_t">Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010; 468:834.</a></li><li><a class="nounderline abstract_t">Yang H, Kim A, David T, et al. TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation. Cell 2012; 151:111.</a></li><li><a class="nounderline abstract_t">Bächli E. History of tissue factor. Br J Haematol 2000; 110:248.</a></li><li><a class="nounderline abstract_t">Mandal SK, Pendurthi UR, Rao LV. Cellular localization and trafficking of tissue factor. Blood 2006; 107:4746.</a></li><li><a class="nounderline abstract_t">Levi M, van der Poll T, Schultz M. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunopathol 2012; 34:167.</a></li><li><a class="nounderline abstract_t">Chen VM, Ahamed J, Versteeg HH, et al. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45:12020.</a></li><li><a class="nounderline abstract_t">Wong JW, Hogg PJ. Analysis of disulfide bonds in protein structures. J Thromb Haemost 2010.</a></li><li><a class="nounderline abstract_t">Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation: Which? Where? When? Arterioscler Thromb Vasc Biol 2009; 29:1989.</a></li><li><a class="nounderline abstract_t">Bach RR, Monroe D. What is wrong with the allosteric disulfide bond hypothesis? Arterioscler Thromb Vasc Biol 2009; 29:1997.</a></li><li><a class="nounderline abstract_t">Kothari H, Nayak RC, Rao LV, Pendurthi UR. Cystine 186-cystine 209 disulfide bond is not essential for the procoagulant activity of tissue factor or for its de-encryption. Blood 2010; 115:4273.</a></li><li><a class="nounderline abstract_t">Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96:2311.</a></li><li><a class="nounderline abstract_t">Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9:458.</a></li><li><a class="nounderline abstract_t">Del Conde I, Shrimpton CN, Thiagarajan P, López JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106:1604.</a></li><li><a class="nounderline abstract_t">Panes O, Matus V, Sáez CG, et al. Human platelets synthesize and express functional tissue factor. Blood 2007; 109:5242.</a></li><li><a class="nounderline abstract_t">Bouchard BA, Mann KG, Butenas S. No evidence for tissue factor on platelets. Blood 2010; 116:854.</a></li><li><a class="nounderline abstract_t">Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86:66.</a></li><li><a class="nounderline abstract_t">Konigsberg W, Kirchhofer D, Riederer MA, Nemerson Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. Thromb Haemost 2001; 86:757.</a></li><li><a class="nounderline abstract_t">Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46:103.</a></li><li><a class="nounderline abstract_t">Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci U S A 1988; 85:2429.</a></li><li><a class="nounderline abstract_t">Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266:7353.</a></li><li><a class="nounderline abstract_t">von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86:3035.</a></li><li><a class="nounderline abstract_t">Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253:909.</a></li><li><a class="nounderline abstract_t">Di Scipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61:1528.</a></li><li><a class="nounderline abstract_t">Sun Y, Gailani D. Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem 1996; 271:29023.</a></li><li><a class="nounderline abstract_t">Kamikubo Y, Mendolicchio GL, Zampolli A, et al. Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex. Blood 2017; 130:1661.</a></li><li><a class="nounderline abstract_t">Weidmann H, Heikaus L, Long AT, et al. The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity. Biochim Biophys Acta Mol Cell Res 2017; 1864:2118.</a></li><li><a class="nounderline abstract_t">Kornberg A, Rao NN, Ault-Riché D. Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem 1999; 68:89.</a></li><li><a class="nounderline abstract_t">Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279:44250.</a></li><li><a class="nounderline abstract_t">Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119:5972.</a></li><li><a class="nounderline abstract_t">Lämmle B, Wuillemin WA, Huber I, et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65:117.</a></li><li><a class="nounderline abstract_t">Colman RW, Bagdasarian A, Talamo RC, et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56:1650.</a></li><li><a class="nounderline abstract_t">Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325:153.</a></li><li><a class="nounderline abstract_t">Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118:6963.</a></li><li><a class="nounderline abstract_t">Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202:271.</a></li><li><a class="nounderline abstract_t">Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002; 87:774.</a></li><li><a class="nounderline abstract_t">Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111:4113.</a></li><li><a class="nounderline abstract_t">Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372:232.</a></li><li><a class="nounderline abstract_t">Cochery-Nouvellon E, Mercier E, Lissalde-Lavigne G, et al. Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy. J Thromb Haemost 2007; 5:700.</a></li><li><a class="nounderline abstract_t">Reuner KH, Jenetzky E, Aleu A, et al. Factor XII C46T gene polymorphism and the risk of cerebral venous thrombosis. Neurology 2008; 70:129.</a></li><li><a class="nounderline abstract_t">Tirado I, Soria JM, Mateo J, et al. Association after linkage analysis indicates that homozygosity for the 46C--&gt;T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 2004; 91:899.</a></li><li><a class="nounderline abstract_t">Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99:2323.</a></li><li><a class="nounderline abstract_t">Minnema MC, Friederich PW, Levi M, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101:10.</a></li><li><a class="nounderline abstract_t">Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992; 29:213.</a></li><li><a class="nounderline abstract_t">Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257:6556.</a></li><li><a class="nounderline abstract_t">Tracy PB, Eide LL, Bowie EJ, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood 1982; 60:59.</a></li><li><a class="nounderline abstract_t">Mann KG, Nesheim ME, Hibbard LS, Tracy PB. The role of factor V in the assembly of the prothrombinase complex. Ann N Y Acad Sci 1981; 370:378.</a></li><li><a class="nounderline abstract_t">Tracy PB, Giles AR, Mann KG, et al. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74:1221.</a></li><li><a class="nounderline abstract_t">Kane WH, Lindhout MJ, Jackson CM, Majerus PW. Factor Va-dependent binding of factor Xa to human platelets. J Biol Chem 1980; 255:1170.</a></li><li><a class="nounderline abstract_t">Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem 1985; 260:2119.</a></li><li><a class="nounderline abstract_t">Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29:177.</a></li><li><a class="nounderline abstract_t">Pisano JJ, Finlayson JS, Peyton MP. [Cross-link in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine]. Science 1968; 160:892.</a></li><li><a class="nounderline abstract_t">Aleman MM, Byrnes JR, Wang JG, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014; 124:3590.</a></li><li><a class="nounderline abstract_t">Greenberg CS, Achyuthan KE, Fenton JW 2nd. Factor XIIIa formation promoted by complexing of alpha-thrombin, fibrin, and plasma factor XIII. Blood 1987; 69:867.</a></li><li><a class="nounderline abstract_t">Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86:959.</a></li><li><a class="nounderline abstract_t">Broze GJ Jr, Warren LA, Novotny WF, et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71:335.</a></li><li><a class="nounderline abstract_t">Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998; 273:4378.</a></li><li><a class="nounderline abstract_t">Jesty J, Wun TC, Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry 1994; 33:12686.</a></li><li><a class="nounderline abstract_t">Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98:2980.</a></li><li><a class="nounderline abstract_t">Huang ZF, Higuchi D, Lasky N, Broze GJ Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90:944.</a></li><li><a class="nounderline abstract_t">Cunha ML, Bakhtiari K, Peter J, et al. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood 2015; 125:1822.</a></li><li><a class="nounderline abstract_t">Vincent LM, Tran S, Livaja R, et al. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα. J Clin Invest 2013; 123:3777.</a></li><li><a class="nounderline abstract_t">Kuang SQ, Hasham S, Phillips MD, et al. Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas. Blood 2001; 97:1549.</a></li><li><a class="nounderline abstract_t">Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78:471.</a></li><li><a class="nounderline abstract_t">Rak J. New checkpoint of the coagulant phenotype. Blood 2014; 124:3511.</a></li><li><a class="nounderline abstract_t">Iqbal MB, Johns M, Cao J, et al. PARP-14 combines with tristetraprolin in the selective posttranscriptional control of macrophage tissue factor expression. Blood 2014; 124:3646.</a></li><li><a class="nounderline abstract_t">Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8:37.</a></li><li><a class="nounderline abstract_t">Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest 1984; 74:341.</a></li><li><a class="nounderline abstract_t">Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24:19.</a></li><li><a class="nounderline abstract_t">Weitz JI. Heparan sulfate: antithrombotic or not? J Clin Invest 2003; 111:952.</a></li><li><a class="nounderline abstract_t">Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257:7944.</a></li><li><a class="nounderline abstract_t">Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264:4743.</a></li><li><a class="nounderline abstract_t">Esmon CT. The protein C pathway. Chest 2003; 124:26S.</a></li><li><a class="nounderline abstract_t">Dutt T, Toh CH. The Yin-Yang of thrombin and activated protein C. Br J Haematol 2008; 140:505.</a></li><li><a class="nounderline abstract_t">Fuentes-Prior P, Iwanaga Y, Huber R, et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000; 404:518.</a></li><li><a class="nounderline abstract_t">Esmon CT, Xu J, Gu JM, et al. Endothelial protein C receptor. Thromb Haemost 1999; 82:251.</a></li><li><a class="nounderline abstract_t">Taylor FB Jr, Peer GT, Lockhart MS, et al. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97:1685.</a></li><li><a class="nounderline abstract_t">Saposnik B, Reny JL, Gaussem P, et al. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004; 103:1311.</a></li><li><a class="nounderline abstract_t">Isermann B, Hendrickson SB, Zogg M, et al. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 2001; 108:537.</a></li><li><a class="nounderline abstract_t">Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256:11128.</a></li><li><a class="nounderline abstract_t">Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270:4053.</a></li><li><a class="nounderline abstract_t">Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63:486.</a></li><li><a class="nounderline abstract_t">O'Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood 2000; 95:1714.</a></li><li><a class="nounderline abstract_t">Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93:2552.</a></li><li><a class="nounderline abstract_t">Castoldi E, Brugge JM, Nicolaes GA, et al. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004; 103:4173.</a></li><li><a class="nounderline abstract_t">Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 1996; 93:10417.</a></li><li><a class="nounderline abstract_t">Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116:4.</a></li><li><a class="nounderline abstract_t">Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989; 259:315.</a></li><li><a class="nounderline abstract_t">Phillips DR, Conley PB, Sinha U, Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost 2005; 3:1577.</a></li><li><a class="nounderline abstract_t">Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325:1137.</a></li><li><a class="nounderline abstract_t">Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002.</a></li><li><a class="nounderline abstract_t">Cozzi MR, Guglielmini G, Battiston M, et al. Visualization of nitric oxide production by individual platelets during adhesion in flowing blood. Blood 2015; 125:697.</a></li><li><a class="nounderline abstract_t">Qiu C, Muchant D, Beierwaltes WH, et al. Evolution of chronic nitric oxide inhibition hypertension: relationship to renal function. Hypertension 1998; 31:21.</a></li><li><a class="nounderline abstract_t">Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf) 2017; 219:22.</a></li><li><a class="nounderline abstract_t">Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 1980; 43:77.</a></li><li><a class="nounderline abstract_t">Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257:2912.</a></li><li><a class="nounderline abstract_t">Samis JA, Ramsey GD, Walker JB, et al. Proteolytic processing of human coagulation factor IX by plasmin. Blood 2000; 95:943.</a></li><li><a class="nounderline abstract_t">Hur WS, Mazinani N, Lu XJ, et al. Coagulation factor XIIIa is inactivated by plasmin. Blood 2015; 126:2329.</a></li><li><a class="nounderline abstract_t">Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003; 89:610.</a></li><li><a class="nounderline abstract_t">Stein CM, Brown N, Vaughan DE, et al. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. J Am Coll Cardiol 1998; 32:117.</a></li><li><a class="nounderline abstract_t">Yamamoto C, Kaji T, Sakamoto M, et al. Calcium regulation of tissue plasminogen activator and plasminogen activator inhibitor-1 release from cultured human vascular endothelial cells. Thromb Res 1994; 74:163.</a></li><li><a class="nounderline abstract_t">van Zonneveld AJ, Veerman H, Pannekoek H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1986; 83:4670.</a></li><li><a class="nounderline abstract_t">Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69:381.</a></li><li><a class="nounderline abstract_t">Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update. Fibrinolysis 1995; 9:263.</a></li><li><a class="nounderline abstract_t">Edelberg JM, Pizzo SV. Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin. Biochem J 1992; 286 ( Pt 1):79.</a></li><li><a class="nounderline abstract_t">Fay WP, Shapiro AD, Shih JL, et al. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327:1729.</a></li><li><a class="nounderline abstract_t">Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90:204.</a></li><li><a class="nounderline abstract_t">Schwartz BS. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism. J Biol Chem 1994; 269:8319.</a></li><li><a class="nounderline abstract_t">Favier R, Aoki N, de Moerloose P. Congenital alpha(2)-plasmin inhibitor deficiencies: a review. Br J Haematol 2001; 114:4.</a></li><li><a class="nounderline abstract_t">Nesheim M. Fibrinolysis and the plasma carboxypeptidase. Curr Opin Hematol 1998; 5:309.</a></li><li><a class="nounderline abstract_t">Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96:2534.</a></li><li><a class="nounderline abstract_t">Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271:16603.</a></li><li><a class="nounderline abstract_t">Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85:5.</a></li><li><a class="nounderline abstract_t">Leung LLK, Morser J. Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity. J Thromb Haemost 2018.</a></li><li><a class="nounderline abstract_t">Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 1998; 273:27220.</a></li><li><a class="nounderline abstract_t">Mosnier LO, Lisman T, van den Berg HM, et al. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86:1035.</a></li><li><a class="nounderline abstract_t">Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88:3815.</a></li><li><a class="nounderline abstract_t">Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99:175.</a></li><li><a class="nounderline abstract_t">Foley JH, Nesheim ME. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2009; 7:453.</a></li><li><a class="nounderline abstract_t">Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85:667.</a></li><li><a class="nounderline abstract_t">Colucci M, Binetti BM, Tripodi A, et al. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103:2157.</a></li><li><a class="nounderline abstract_t">van der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis. Curr Vasc Pharmacol 2012; 10:632.</a></li><li><a class="nounderline abstract_t">Vazquez-Garza E, Jerjes-Sanchez C, Navarrete A, et al. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis 2017; 44:377.</a></li><li><a class="nounderline abstract_t">Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13:34.</a></li><li><a class="nounderline abstract_t">Kho S, Barber BE, Johar E, et al. Platelets kill circulating parasites of all major Plasmodium species in human malaria. Blood 2018; 132:1332.</a></li><li><a class="nounderline abstract_t">Esmon CT. Protein C anticoagulant system--anti-inflammatory effects. Semin Immunopathol 2012; 34:127.</a></li><li><a class="nounderline abstract_t">Griffin JH, Mosnier LO, Fernández JA, Zlokovic BV. 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C. Arterioscler Thromb Vasc Biol 2016; 36:2143.</a></li><li><a class="nounderline abstract_t">Leung LL, Myles T, Nishimura T, et al. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008; 45:4080.</a></li><li class="breakAll">Leung L, Morser J. Hemostasis and Vascular Inflammation. In: Inflammatory Diseases of Blood Vessels, Second Edition, Hoffman GS, Weyand CM, Langford CA, et al (Eds), Wiley-Blackwell, Oxford, UK 2012. p.105.</li><li><a class="nounderline abstract_t">Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006; 32:33.</a></li><li><a class="nounderline abstract_t">Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 2007; 5 Suppl 1:24.</a></li><li><a class="nounderline abstract_t">Liang HP, Kerschen EJ, Basu S, et al. Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood 2015; 126:2415.</a></li></ol></div><div id="topicVersionRevision">Topic 1371 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994286" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Directing thrombin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753650" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mechanisms of thrombus formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296928" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Coordination of platelet agonist signaling during the hemostatic response in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10605726" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Collagen receptor signaling in platelets and megakaryocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102047" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Protease-activated receptors in hemostasis, thrombosis and vascular biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001069" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thrombin signalling and protease-activated receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970120" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thrombin and platelet activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16952995" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Protease-activated receptors in cardiovascular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9716134" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A dual thrombin receptor system for platelet activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22443427" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vorapaxar in the secondary prevention of atherothrombotic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077816" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25792124" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy and safety of vorapaxar as approved for clinical use in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17380206" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11196645" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Identification of the platelet ADP receptor targeted by antithrombotic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9198164" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Platelet GPIb-V-IX complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23929303" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bernard-Soulier syndrome: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9198192" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Platelet adhesion to collagen: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565074" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/574143" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Exposure of platelet fibrinogen receptors by ADP and epinephrine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1597464" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531572" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Integrin signaling: the platelet paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840725" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9916135" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2669994" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Biochemical mechanisms of platelet activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9743506" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2180467" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The origin and physiological relevance of alpha-granule adhesive proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799560" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Platelets, petechiae, and preservation of the vascular wall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18274674" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18292814" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A critical role for extracellular protein disulfide isomerase during thrombus formation in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7989579" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Production and characterization of transformed B-lymphocytes expressing the membrane defect of Scott syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12231555" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Platelets and thrombin generation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27207787" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705491" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719406" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Murine coagulation factor VIII is synthesized in endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129023" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Post-translational modifications in proteins involved in blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10068650" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8578528" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The tissue factor pathway: how it has become a "prima ballerina".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16500122" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Models of blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19765210" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The molecular basis of factor V and VIII procofactor activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24869936" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : New insights into the spatiotemporal localization of prothrombinase in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261172" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4416355" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The mechanism of activation of factor X. Kinetic control of alternative pathways leading to the formation of activated factor X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8663201" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/271951" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6722352" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3967085" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The role of activated human platelets in prothrombin and factor X activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35427420" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cryo-EM structure of the prothrombin-prothrombinase complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16888445" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The endothelial protein C receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23809130" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The transition of prothrombin to thrombin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2793843" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608230" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9716599" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Expression of proteins controlling transbilayer movement of plasma membrane phospholipids in the B lymphocytes from a patient with Scott syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107324" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Calcium-dependent phospholipid scrambling by TMEM16F.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021219" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971380" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : History of tissue factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16493004" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cellular localization and trafficking of tissue factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21805225" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Systemic versus localized coagulation activation contributing to organ failure in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17002301" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Evidence for activation of tissue factor by an allosteric disulfide bond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456749" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Analysis of disulfide bonds in protein structures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19592470" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Tissue factor in coagulation: Which? Where? When?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19923558" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : What is wrong with the allosteric disulfide bond hypothesis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20237315" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cystine 186-cystine 209 disulfide bond is not essential for the procoagulant activity of tissue factor or for its de-encryption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051638" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Blood-borne tissue factor: another view of thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12652293" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741221" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17347408" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Human platelets synthesize and express functional tissue factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688968" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : No evidence for tissue factor on platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487043" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Tissue factor: an enzyme cofactor and a true receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11583305" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7598447" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Tissue factor pathway inhibitor and the revised theory of coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3128786" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019570" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579397" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1652157" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Factor XI activation in a revised model of blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/659613" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Activation of human factor IX (Christmas factor).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8910554" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Identification of a factor IX binding site on the third apple domain of activated factor XI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28729433" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28743596" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10872445" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Inorganic polyphosphate: a molecule of many functions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15308650" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517894" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1905067" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1202089" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2052060" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Factor XI deficiency in Ashkenazi Jews in Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976677" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Polyphosphate is a cofactor for the activation of factor XI by thrombin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009717" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Defective thrombus formation in mice lacking coagulation factor XII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268095" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Reduced incidence of ischemic stroke in patients with severe factor XI deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25482425" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Factor XI antisense oligonucleotide for prevention of venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17408404" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180442" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Factor XII C46T gene polymorphism and the risk of cerebral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15116249" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Association after linkage analysis indicates that homozygosity for the 46C--&gt;T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153272" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9421460" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1641667" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Surface-dependent hemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7076681" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Thrombin-catalyzed activation of human coagulation factor V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7082847" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Radioimmunoassay of factor V in human plasma and platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7023322" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The role of factor V in the assembly of the prothrombinase complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6480825" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7356655" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Factor Va-dependent binding of factor Xa to human platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3972783" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Human prothrombinase complex assembly and function on isolated peripheral blood cell populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1641664" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The roles of fibrinogen and fibrin in hemostasis and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4967475" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : [Cross-link in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24983320" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Factor XIII activity mediates red blood cell retention in venous thrombi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2880615" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Factor XIIIa formation promoted by complexing of alpha-thrombin, fibrin, and plasma factor XIII.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11686353" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Structure and biology of tissue factor pathway inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3422166" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9468488" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7918495" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11698280" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242522" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25634741" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23979162" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238089" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9198199" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Tissue factor pathway inhibitor: potential therapeutic applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25477483" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : New checkpoint of the coagulant phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25293769" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : PARP-14 combines with tristetraprolin in the selective posttranscriptional control of macrophage tissue factor expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205009" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Antithrombin and its inherited deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6746897" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9515776" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Antithrombin: its physiological importance and role in DIC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12671043" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Heparan sulfate: antithrombotic or not?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6282863" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2538457" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The roles of protein C and thrombomodulin in the regulation of blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970121" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The protein C pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18275428" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The Yin-Yang of thrombin and activated protein C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10761923" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10605711" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Endothelial protein C receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238108" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Endothelial cell protein C receptor plays an important role in protein C activation in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576048" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11518727" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6457049" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7876154" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Characterization of the molecular defect in factor VR506Q.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6419799" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688829" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194434" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14976057" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8816815" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16395396" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2655580" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : The eicosanoids and their biochemical mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102022" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Therapeutic approaches in arterial thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1891022" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7504210" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : The L-arginine-nitric oxide pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25480660" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Visualization of nitric oxide production by individual platelets during adhesion in flowing blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9449385" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Evolution of chronic nitric oxide inhibition hypertension: relationship to renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26706498" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Endothelial dysfunction and vascular disease - a 30th anniversary update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6450468" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7199524" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648407" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Proteolytic processing of human coagulation factor IX by plasmin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26359437" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Coagulation factor XIIIa is inactivated by plasmin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12669114" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Molecular and cellular modulation of fibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669258" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8029817" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Calcium regulation of tissue plasminogen activator and plasminogen activator inhibitor-1 release from cultured human vascular endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3088564" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Autonomous functions of structural domains on human tissue-type plasminogen activator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3099859" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Plasminogen activator inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381585" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1435917" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207454" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7907591" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472338" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Congenital alpha(2)-plasmin inhibitor deficiencies: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9776208" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Fibrinolysis and the plasma carboxypeptidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593646" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Plasma carboxypeptidases as regulators of the plasminogen system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8663147" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11204587" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29883024" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9765243" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11686321" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8916945" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756168" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19087221" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11341503" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630828" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22272914" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Crosstalk between inflammation and coagulation: the lessons of sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28730407" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23222502" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Thrombosis as an intravascular effector of innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30026183" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Platelets kill circulating parasites of all major Plasmodium species in human malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21822632" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Protein C anticoagulant system--anti-inflammatory effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27758767" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18706698" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18706698" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16479460" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Tissue factor in infection and severe inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635705" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Fibrin and fibrinolysis in infection and host defense.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341257" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
